ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

A Single Center's Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving an HCV Positive Kidney.

N. Kapila,1 B. Zervos,2 B. Ismail,1 G. Schnickel,2 J. Rivas,2 D. Reino,2 N. Agrawal,2 A. Tzakis.2

1Gastroenterology/Hepatology, Cleveland Clinic, Weston, FL
2Transplant, Cleveland Clinic, Weston, FL

Meeting: 2017 American Transplant Congress

Abstract number: C21

Keywords: Donors, Hepatitis C, Kidney transplantation, marginal, Viral therapy

Session Information

Session Name: Poster Session C: Deceased Donor Issues II: DCD, DGF, AKI, En-Bloc

Session Type: Poster Session

Date: Monday, May 1, 2017

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Background: Nearly 8% of patients in the U.S. undergoing hemodialysis are Hepatitis C (HCV) positive. There is a survival benefit in HCV positive patients who receive an HCV positive kidney as opposed to remaining on dialysis. Despite this, HCV positive organs are underutilized. Herein, we present a single center's experience with DAAs in HCV positive patients who receive an HCV positive graft.

Methods: We conducted a retrospective chart review, including patients from March of 2015 till present. Those patients who were HCV positive and received an HCV positive kidney and then treated with DAAs were included.

Results: 8 HCV positive patients received HCV positive grafts. 6 of the 8 patients have started HCV treatment at the time of writing this abstract.

Genotype Pre-Treatment Viral Load Duration of Sofosbuvir/Ledipasvir Therapy Response to Treatent
1 1b 245.000 12 weeks SVR
2 1a 1.570.000 12 weeks SVR
3 1b 301,000 12 weeks SVR
4 1a 2,350,000 12 weeks SVR
5 1a 11,400,000 12 weeks ETR
6 2b 66,700 12 weeks n/a

Anti-viral therapy was initiated at a median of 12 weeks post kidney transplantation. All patients were on a Tacrolimus, Prednisone, and Mycophenolate Mofetil based immunosuppression regimen. 1 patient required adjustment of their Tacrolimus due to interaction with the anti-viral therapy.

Discussion: HCV positive kidneys remain underutilized. Considering the overall benefit of receiving an HCV positive graft over remaining on dialysis, there is opportunity to expand the donor pool, decrease wait times, and improve survival. Our case series demonstrates a remarkable response to Sofosbuvir based anti-viral regimens when used in HCV positive patients receiving HCV positive kidneys. The patients in our case series were given empiric anti-HCV treatment regardless of degree of liver fibrosis or viral load. Our particular case series is unique in that it describes the empiric initiation of DAAs in HCV positive patients receiving an HCV positive graft. While further studies are required to confirm our experience, the remarkable response to DAAs may further change our approach to HCV positive grafts.

CITATION INFORMATION: Kapila N, Zervos B, Ismail B, Schnickel G, Rivas J, Reino D, Agrawal N, Tzakis A. A Single Center's Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving an HCV Positive Kidney. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Kapila N, Zervos B, Ismail B, Schnickel G, Rivas J, Reino D, Agrawal N, Tzakis A. A Single Center's Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving an HCV Positive Kidney. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/a-single-centers-experience-of-direct-acting-anti-viral-agents-in-hcv-positive-patients-receiving-an-hcv-positive-kidney/. Accessed May 9, 2025.

« Back to 2017 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences